Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Dec 28, 2013; 19(48): 9328-9333
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9328
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9328
Latent hepatitis B is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C
Arvind Reddy, Elizabeth May, Murray Ehrinpreis, Milton Mutchnick, Division of Gastroenterology, Wayne State University, Detroit, MI 48201, United States
Author contributions: All the authors contributed to this manuscript.
Correspondence to: Arvind Reddy, MD, Division of Gastroenterology, Wayne State University, 6-Hudson c/o Milton Mutchnick, MD 3990 John R, Detroit, MI 48201, United States. areddygi@yahoo.com
Telephone: +1-313-5772424 Fax: +1-313-5772233
Received: August 9, 2013
Revised: August 21, 2013
Accepted: September 4, 2013
Published online: December 28, 2013
Processing time: 158 Days and 8.8 Hours
Revised: August 21, 2013
Accepted: September 4, 2013
Published online: December 28, 2013
Processing time: 158 Days and 8.8 Hours
Core Tip
Core tip: Latent hepatitis B (LHB) has recently received significant attention among researchers and clinicians managing chronic liver disease. It is defined as a combination of hepatitis B surface antigen negative and hepatitis B core antibody positive. The potential association of LHB with hepatocellular carcinoma among patients with chronic hepatitis C infection has been studied and reported in this manuscript.